Viatris (VTRS) Stock Overview
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
VTRS Community Fair Values
Create NarrativeSee what 64 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Viatris Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.19 |
| 52 Week High | US$13.55 |
| 52 Week Low | US$6.85 |
| Beta | 0.89 |
| 1 Month Change | -3.41% |
| 3 Month Change | 9.33% |
| 1 Year Change | -12.08% |
| 3 Year Change | 16.59% |
| 5 Year Change | -34.85% |
| Change since IPO | 1,561.86% |
Recent News & Updates
Recent updates
Viatris: Indore Plant Could Boost 2026 Numbers
Sep 25
New Product Launches And Expense Savings Will Strengthen Future Operations
New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.Viatris: One Swallow Doesn't Make A Summer
Feb 27Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
Jan 24Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes
Jan 06Bargain Priced Viatris Reports Strong Q3 Earnings Results
Nov 08Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy
Oct 22Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope
Jun 13Viatris: Skeptics Proven Right Once Again
May 30Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.
Apr 24Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential
Apr 08Viatris Stock Is Still Worth Buying
Mar 30Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued
Mar 02From Euphoria To Reality: Viatris' Tale Of Market Whirlwind
Jan 12Shareholder Returns
| VTRS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 7.0% | 10.3% | 1.2% |
| 1Y | -12.1% | -2.2% | 17.9% |
Return vs Industry: VTRS underperformed the US Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: VTRS underperformed the US Market which returned 18.7% over the past year.
Price Volatility
| VTRS volatility | |
|---|---|
| VTRS Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VTRS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VTRS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1961 | 32,000 | Scott Smith | www.viatris.com |
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.
Viatris Inc. Fundamentals Summary
| VTRS fundamental statistics | |
|---|---|
| Market cap | US$11.79b |
| Earnings (TTM) | -US$3.47b |
| Revenue (TTM) | US$14.12b |
Is VTRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTRS income statement (TTM) | |
|---|---|
| Revenue | US$14.12b |
| Cost of Revenue | US$8.35b |
| Gross Profit | US$5.77b |
| Other Expenses | US$9.24b |
| Earnings | -US$3.47b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 06, 2025
| Earnings per share (EPS) | -2.97 |
| Gross Margin | 40.86% |
| Net Profit Margin | -24.57% |
| Debt/Equity Ratio | 93.2% |
How did VTRS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 06:42 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Viatris Inc. is covered by 42 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| David Maris | BMO Capital Markets Equity Research |